EMA accepts MAA for LCP-Tacro

Veloxis Pharmaceuticals A/S (CSE:VELO) said EMA accepted for review an MAA for LCP-Tacro tacrolimus to prevent organ rejection in kidney transplant patients. The company said it expects a decision on ...